Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Wedbush Downgrades Freeline Therapeutics to Neutral, Lowers Price Target to $5

Author: Benzinga Newsdesk | October 18, 2023 10:35am
Wedbush analyst David Nierengarten downgrades Freeline Therapeutics (NASDAQ:FRLN) from Outperform to Neutral and lowers the price target from $8 to $5.

Posted In: FRLN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist